Product information:
| Product name |
Dihydroartemisinin + Piperaquine tablets |
| Indication |
It is used to treat falciparum malaria and vivax malaria. |
| Specifications |
Each tablet contained 40 mg dihydroartemisinin and 320 mg piperaquine phosphate. |
| Packing |
8 pieces / blister / box, packed with aluminum plastic blister. |
| Term of validity |
2 years |
| Storage |
Store in a cool and dry place. |
Pharmacology and Toxicology:
This product is a compound preparation composed of dihydroartemisinin and piperaquine phosphate.
Dihydroartemisinin is a derivative of artemisinin, which is the active substance in vivo of artemisinin. It has strong killing effect on Plasmodium clones, and can quickly kill Plasmodium and control symptoms. The results of drug resistance cultivation showed that Plasmodium was not easy to develop resistance to dihydroartemisinin.
Piperaquine phosphate is a 4-aminoquinoline antimalarial drug. Its antimalarial effect is similar to that of chloroquine. It affects the ultrastructure of Plasmodium erythrocytic schizoites, and mainly causes the swelling of food vesicles and mitochondria of trophozoites, resulting in the destruction of their physiological functions, thus killing the Plasmodium. There was no cross resistance between piperaquine phosphate and chloroquine.
In vitro pharmacodynamic studies showed that the combination of the two drugs could increase the efficacy and delay the development of drug resistance of Plasmodium falciparum.
Pharmacokinetics:
The drug is well absorbed by oral administration and takes effect quickly.
After oral administration of dihydroartemisinin 2mg / kg, the plasma concentration of dihydroartemisinin reached the peak value at 1.33h, and the maximum blood concentration was 0.71 μ g / ml. Plasma T1 / 2 was 1.57 hours. It is widely distributed in the body and excreted and metabolized rapidly.
The absorption rate of piperaquine phosphate was 80% - 90% in 24 hours. After absorption, it was distributed in liver, kidney, lung, spleen and other tissues. Within 8 hours after administration, the dosage of piperaquine phosphate in liver could reach about 1 / 4 of the total dose. The drug disappeared slowly in vivo, T1 / 2 was 9.4 days. The drug was excreted with bile and there was hepatic and intestinal circulation.
Matters needing attention:
1. This product has no antipyretic effect;
2. Patients with liver and kidney dysfunction should be used with caution;
3. Use this product in strict accordance with the prescribed usage and dosage. If the clinical symptoms are not improved, please consult a doctor in time;
4. The half-life of piperaquine phosphate in this product is long, and it should not be taken repeatedly within half a month.
Adverse reactions:
The main adverse reactions of this product are less, mainly caused by piperaquine phosphate, as follows:
1. Gastrointestinal reactions: nausea, vomiting, anorexia, abdominal pain, diarrhea, etc;
2. Nervous system: such as dizziness, headache, deafness, poor sleep, etc;
3. Allergic reactions: pruritus, rash, etc;
4. Laboratory examination abnormalities: such as transient decrease of peripheral red blood cells, transient increase of SGPT and SGOT, and increase of serum creatinine.
The following patients are prohibited:
1. Those who are allergic to any drug component in this product;
2. Pregnant women;
3. Severe liver and kidney diseases, blood diseases (such as leucopenia, thrombocytopenia, etc.) and other patients.
Audited Supplier 
Audited Supplier 
){kind=link}
){kind=link}